Drug Trial Radar · NCT07487766
The Safety and Efficacy of XytriX (Umbilical Cord-Derived Mesenchymal Stem Cells) in the Treatment of Knee Osteoarthritis
Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
May 2026
Primary completion
May 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- TricelX Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to study the safety and efficacy of XytriX, an umbilical cord-derived stem cell product, in the treatment of Grade I-IV knee osteoarthritis.
Conditions
- Osteoarthritis
Interventions
Mesenchymal Stem Cell InjectionBiological
Subjects will receive an intra-articular injection of mesenchymal stem cells derived from umbilical cord tissue
Primary outcomes
What the sponsor says the trial is designed to measure.
- Knee Injury and Osteoarthritis Outcome ScoreTime frame: 24 months
- Western Ontario and McMaster Universities Osteoarthritis IndexTime frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
TriCelX
Frisco, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.